Abstract
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis that follows an indolent and progressive course. A delay in diagnosis and treatment may lead to irreversible changes such as erosive arthritis, which lead to permanent physical disability and deformity. Administration of a well-designed screening tool can increase detection of PsA and help determine the prevalence of PsA in a given population. Several tools have been developed to help clinicians screen for PsA. Members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis recently led an effort to develop and validate three PsA screening tools: the Psoriatic Arthritis Screening and Evaluation tool, the Psoriasis Epidemiology Screening Tool, and the Toronto Psoriatic Arthritis Screen.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance, •• Of major importance
Zachariae H: Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003, 4:441–447.
Mease P, Goffe BS: Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 2005, 52:1–19.
Brockbank J, Gladman D: Diagnosis and management of psoriatic arthritis. Drugs 2002, 62:2447–2457.
Gladman DD, Brockbank J: Psoriatic arthritis. Expert Opin Investig Drugs 2000, 9:1511–1522.
Taylor W, Gladman D, Helliwell P, et al.: Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006, 54:2665–2673.
Peloso PM, Hull P, Reeder B: The psoriasis and arthritis questionnaire (PAQ) in detection of arthritis among patients with psoriasis. Arthritis Rheum 1997, 40:S64.
Alenius GM, Stenberg B, Stenlund H, et al.: Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire. J Rheumatol 2002, 29:2577–2582.
• Qureshi AA, Dominguez P, Duffin KC, et al.: Psoriatic arthritis screening tools. J Rheumatol 2008, 35:1423–1425. This is an update on the development of screening tools for PsA that was presented during the 2009 GRAPPA annual meeting. It includes feedback from GRAPPA members on what should constitute an effective screening tool.
• Husni ME, Meyer KH, Cohen DS, et al.: The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol 2007, 57:581–587. This was the first validation pilot study of the PASE questionnaire, jointly developed by rheumatologists and dermatologists, which shows the PASE to be an effective screening tool to identify inflammatory arthritis and to distinguish it from noninflammatory arthritis.
•• Dominguez PL, Husni ME, Holt EW, et al.: Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire. Arch Dermatol Res 2009, 301:573–579. This was the second validation study of the PASE questionnaire in a larger patient population that showed the PASE to be sensitive to change and to have test–retest reliability.
Gladman DD, Schentag CT, Tom B, et al.: Development and validation of a screening questionnaire for psoriatic arthritis. Arthritis Rheum 2007, 56(Suppl 9):S798.
•• Gladman DD, Schentag CT, Tom BD, et al.: Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis 2009, 68:497–501. This article describes the initial development of the ToPAS questionnaire, a psoriasis and PsA screening tool, and its validation in various clinical settings.
•• Ibrahim GH, Buch MH, Lawson C, et al.: Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol 2009, 27:469–474. This article describes the development and validation of the PEST questionnaire, a PsA screening tool, in a community-based setting.
Gelfand JM, Gladman DD, Mease PJ, et al.: Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005, 53:573.
Feldman SR, Fleischer AB Jr, Cooper JZ: New topical treatments change the pattern of treatment of psoriasis: dermatologists remain the primary providers of this care. Int J Dermatol 2000, 39:41–44.
Alenius GM, Stenberg B, Stenlund H, et al.: Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire. J Rheumatol 2002, 29:2577–2582.
Disclosure
Dr. Gladman has received honoraria and/or grant support from Abbott Laboratories, Amgen, Bristol-Myers Squibb, Centocor Ortho Biotech, Schering-Plough, Wyeth, and Pfizer.
Dr. Mease has received research grants from Abbott Laboratories, Amgen, Biogen Idec, Bristol-Myers Squibb, Centocor, Genentech, Roche, Wyeth, and Pfizer; has served as a consultant for Abbott Laboratories, Amgen, Biogen Idec, Bristol-Myers Squibb, Centocor, Genentech, Roche, UCB, Wyeth, and Pfizer; and has served as a speaker for Abbott Laboratories, Amgen, Biogen Idec, Bristol-Myers Squibb, Centocor, Genentech, UCB, Wyeth, and Pfizer.
Dr. Husni has served as a consultant for Amgen and Genentech.
Dr. Qureshi has served as a consultant for Amgen and Genentech. No other potential conflicts of interest relevant to this article were reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dominguez, P., Gladman, D.D., Helliwell, P. et al. Development of Screening Tools to Identify Psoriatic Arthritis. Curr Rheumatol Rep 12, 295–299 (2010). https://doi.org/10.1007/s11926-010-0113-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11926-010-0113-2